|
|
111 Barclay Boulevard
Lincolnshire, IL 60069 USA
phone:847.478.0500
fax:847.478.9152
|
|
| Symbol |
BPAX |
| Exchange |
NASDAQ |
| Founded |
1996 |
| Employees |
23 |
|
|
| www.biosantepharma.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Develops products for female sexual health, menopause, contraception and male hypogonadism |
|
| Management |
| Stephen M. Simes (President and Chief Executive Officer); Phillip B. Donenberg, CPA (Chief Financial Officer, Treasurer and Secretary); Bill Milling (Controller and Senior Director of Operations); Michael C. Snabes (Vice President of Clinical Development) |
| |
|
|
|
|
|
|
|
| Keywords |
| pharmaceutical, sexual health, menopause, contraception, hypogonadism, novel vaccines |
|
|
|
| Description |
|
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. |
|
| Products / Services |
The company's products include LibiGel, a transdermal testosterone gel in Phase III development for the treatment of female sexual dysfunction; Elestrin, a transdermal estradiol (estrogen) gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause; Bio-T-Gel, a transdermal testosterone gel in development for the treatment of hypogonadism, or testosterone deficiency in men; and the Pill-Plus for the treatment of female sexual dysfunction in women using oral or transdermal contraceptives.
The company's CaP products in development comprise BioLook, which is facial line filler in development using proprietary CaP technology in the area of aesthetic medicine; BioVant for the treatment of viral and bacterial infections and autoimmune diseases; BioOral, a delivery system using CaP technology for oral/buccal/intranasal administration of proteins and other therapies; and BioAir, a delivery system using CaP technology for inhalable versions of proteins and other therapies.
|
|
| Technology / Differentiation |
| BioLook is also developing calcium phosphate nanotechnology for aesthetic medicine, novel vaccines, and drug delivery. |
|
| Market / Customers |
LibiGel is the only product in active development in the U.S. for the treatment of female sexual dysfunction disorder, specifically, hypoactive sexual desire disorder in menopausal women.
Elestrin competes in the estrogen marker specifically for the treatment of hot flashes.
The current market for testosterone and estrogen products is approximately $2.5 billion dollars in the U.S. alone, with estimates for female sexual dysfunction potentially adding $2.0 - $4.0 billion, and the current market for hormonal contraception is approximately $3.0 billion.
|
|
| Competitors / Substitutes / Alternatives |
Upsher-Smith Laboratories, Inc., Noven Pharmaceuticals, Inc., Wyeth, Auxilium Pharmaceuticals, Inc., Ascend Therapeutics, Inc., Watson Pharmaceuticals, Inc., KV Pharmaceutical Co., Solvay Pharmaceuticals, Inc., GlaxoSmithKline plc, Sanofi-aventis and Merck & Co., Inc.
|
|
| Status |
| In September 2008, the Company announced the results of clinical work on its Pill-Plus triple hormone therapy oral contraceptive. The Pill-Plus adds a third hormone, an androgen, to the normal two hormone (estrogen and progestogen) oral contraceptive to prevent androgen deficiency. The Pill-Plus is designed to improve the condition known as female sexual dysfunction in oral contraceptive users. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
